375 related articles for article (PubMed ID: 22689690)
1. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
2. Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C.
Mammen JS; Ghazarian SR; Rosen A; Ladenson PW
Thyroid; 2013 Sep; 23(9):1151-8. PubMed ID: 23517287
[TBL] [Abstract][Full Text] [Related]
3. Thyroid dysfunction in a UK hepatitis C population treated with interferon-alpha and ribavirin combination therapy.
Costelloe SJ; Wassef N; Schulz J; Vaghijiani T; Morris C; Whiting S; Thomas M; Dusheiko G; Jacobs M; Vanderpump MP
Clin Endocrinol (Oxf); 2010 Aug; 73(2):249-56. PubMed ID: 20148905
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis.
Kee KM; Lee CM; Wang JH; Tung HD; Changchien CS; Lu SN; Wang PW
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):319-26. PubMed ID: 16460494
[TBL] [Abstract][Full Text] [Related]
5. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
Obołończyk Ł; Siekierska-Hellmann M; Wiśniewski P; Lewczuk A; Berendt-Obołończyk M; Lakomy A; Michalska Z; Radowska D; Moszkowska G; Bianek-Bodzak A; Sworczak K
Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):842-849. PubMed ID: 29039351
[TBL] [Abstract][Full Text] [Related]
7. Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study.
Bini EJ; Mehandru S
Arch Intern Med; 2004 Nov; 164(21):2371-6. PubMed ID: 15557418
[TBL] [Abstract][Full Text] [Related]
8. Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C.
Hsieh MC; Yu ML; Chuang WL; Shin SJ; Dai CY; Chen SC; Lin ZY; Hsieh MY; Liu JF; Wang LY; Chang WY
Eur J Endocrinol; 2000 May; 142(5):431-7. PubMed ID: 10802518
[TBL] [Abstract][Full Text] [Related]
9. Can pegylated interferon α 2a cause development of thyroid disorders in patients with chronic hepatitis B?
Kozielewicz D; Zaleśna A; Dybowska D
Expert Opin Drug Saf; 2014 Aug; 13(8):1009-14. PubMed ID: 24930451
[TBL] [Abstract][Full Text] [Related]
10. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
Serranti D; Indolfi G; Nebbia G; Cananzi M; D'Antiga L; Ricci S; Stagi S; Azzari C; Resti M;
Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
[TBL] [Abstract][Full Text] [Related]
11. Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report.
Gill G; Bajwa H; Strouhal P; Buch HN
J Med Case Rep; 2016 Sep; 10(1):253. PubMed ID: 27632981
[TBL] [Abstract][Full Text] [Related]
12. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy.
Marazuela M; García-Buey L; González-Fernández B; García-Monzón C; Arranz A; Borque MJ; Moreno-Otero R
Clin Endocrinol (Oxf); 1996 Jun; 44(6):635-42. PubMed ID: 8759175
[TBL] [Abstract][Full Text] [Related]
13. [Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction].
Obołończyk L; Obołończyk L; Siekierska-Hellmann M; Sworczak K
Postepy Hig Med Dosw (Online); 2007 Jun; 62():309-21. PubMed ID: 18583950
[TBL] [Abstract][Full Text] [Related]
14. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis.
Rotondi M; Minelli R; Magri F; Leporati P; Romagnani P; Baroni MC; Delsignore R; Serio M; Chiovato L
Eur J Endocrinol; 2007 Apr; 156(4):409-14. PubMed ID: 17389454
[TBL] [Abstract][Full Text] [Related]
15. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration.
Boelaert K; Horacek J; Holder RL; Watkinson JC; Sheppard MC; Franklyn JA
J Clin Endocrinol Metab; 2006 Nov; 91(11):4295-301. PubMed ID: 16868053
[TBL] [Abstract][Full Text] [Related]
16. Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C.
Nadeem A; Aslam M; Khan DA; Hussain T; Khan SA
J Coll Physicians Surg Pak; 2009 Feb; 19(2):86-9. PubMed ID: 19208310
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha-induced thyroid dysfunction in patients with chronic active hepatitis C: a transient, reversible and self-limited dysfunction.
Tsuboi K; Katayama M; Yuasa R; Matoba H; Nagayama T; Ihara F; Ooya T; Matsuo K; Otsuka S; Miyachi Y
Intern Med; 1998 Jan; 37(1):27-31. PubMed ID: 9510396
[TBL] [Abstract][Full Text] [Related]
18. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.
Custro N; Montalto G; Scafidi V; Soresi M; Gallo S; Tripi S; Notarbartolo A
J Endocrinol Invest; 1997; 20(7):374-80. PubMed ID: 9309534
[TBL] [Abstract][Full Text] [Related]
19. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
20. Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin.
Danilovic DL; Mendes-Correa MC; Chammas MC; Zambrini H; Marui S
Clinics (Sao Paulo); 2011; 66(10):1757-63. PubMed ID: 22012048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
